上海仁度生物科技股份有限公司 董事会薪酬与考核委员会工作细则 2 第九条 薪酬与考核委员会负责制定董事、高级管理人员的考核标准并进行考核， 制定、审查董事、高级管理人员的薪酬政策与方案，并就下列事项向董事 会提出建议： (一) 董事、高级管理人员的薪酬； (二) 制定或者变更股权激励计划、员工持股计划，激励对象获授权益、 行使权益条件成就； (三) 董事、高级管理人员在拟分拆所属子公司安排持股计划； (四) 董事会授权的其他事宜。 第十条 董事会有权否决损害股东利益的薪酬计划或方案。董事会对薪酬与考核委 员会的建议未采纳或者未完全采纳的，应当在董事会决议中记载薪酬与考 核委员会的意见及未采纳的具体理由，并进行披露。 第十一条 薪酬与考核委员会提出的公司董事的薪酬计划，须报经董事会同意后，提 交股东会审议通过后方可实施；公司高级管理人员的薪酬分配方案须报董 事会批准。 第十二条 薪酬与考核委员会下设的工作组负责做好薪酬与考核委员会决策的前期 准备工作，提供公司有关方面的资料： (一) 提供公司主要财务指标和经营目标完成情况； (二) 公司高级管理人员分管工作范围及主要职责情况； (三) 提供董事及高级管理人员岗 ...

公司发现控股股东、实际控制人及其他关联人占用募集资金的，应当及 时要求归还，并披露占用发生的原因、对公司的影响、清偿整改方案及 整改进展情况。 上海仁度生物科技股份有限公司 募集资金管理制度 第一章 总则 公司募集资金应当投资于科技创新领域，促进新质生产力发展。 公司发行股份、可转换公司债券购买资产并募集配套资金用途另有规定 的，从其规定。 本条第一款所称财务性投资的理解和适用，参照《<上市公司证券发行注 册管理办法>第九条、第十条、第十一条、第十三条、第四十条、第五十 七条、第六十条有关规定的适用意见——证券期货法律适用意见第 18 号》有关规定执行。 1 第一条 为规范上海仁度生物科技股份有限公司（以下简称"公司"）募集资金的 存储、使用与管理，提高募集资金的使用效率和效益，保障募集资金的 安全，维护投资者的合法权益，根据《中华人民共和国公司法》《中华人 民共和国证券法》《上市公司募集资金监管规则》《上海证券交易所科创 板股票上市规则》（以下简称"《上市规则》"）、《上海证券交易所科创板 上市公司自律监管指引第 1 号--规范运作》（以下简称"《规范运作指引》"） 等有关法律、法规、规章、规范性文件以及《 ...

Market Overview - On October 28, the medical device sector rose by 0.21%, led by Chutian Technology, while the Shanghai Composite Index closed at 3988.22, down 0.22%, and the Shenzhen Component Index closed at 13430.1, down 0.44% [1]. Top Performers - Chutian Technology (300358) closed at 11.32, with a significant increase of 20.04% and a trading volume of 842,800 shares, amounting to a transaction value of 924 million yuan [1]. - Libang Instruments (300206) saw a closing price of 13.97, up 15.45%, with a trading volume of 521,600 shares and a transaction value of 718 million yuan [1]. - Zhend Medical (603301) closed at 80.95, increasing by 10.00%, with a trading volume of 159,900 shares [1]. Underperformers - Sino Medical (688108) experienced a decline of 9.39%, closing at 25.19, with a trading volume of 415,300 shares and a transaction value of 1.084 billion yuan [2]. - Yingke Medical (300677) closed at 38.56, down 8.58%, with a trading volume of 333,700 shares [2]. - Nanwei Medical (688029) saw a decrease of 6.30%, closing at 81.52, with a trading volume of 56,100 shares [2]. Capital Flow - The medical device sector experienced a net outflow of 405 million yuan from institutional investors, while retail investors saw a net inflow of 417 million yuan [2][3]. - Chutian Technology had a net inflow of 162.16 million yuan from institutional investors, while retail investors had a net outflow of 64.44 million yuan [3]. - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are actively buying [2][3].

Core Points - On September 29, a total of 25 listed companies had their restricted shares unlocked, with a total market value of approximately 24.818 billion yuan [1] Summary by Category Restricted Share Unlocking - The companies involved in the unlocking of restricted shares include: - Luzhou Laojiao (000568) with 102,700 shares from equity incentive restrictions - East China Pharmaceutical (000963) with 215,000 shares from equity incentive restrictions - Taiyuan Heavy Industry (600169) with 11.6502 million shares from equity incentive restrictions - Jinfat Technology (600143) with 7.406 million shares from equity incentive restrictions - Guotai Junan (601211) with 3.2495 million shares from equity incentive restrictions - Guanglian Da (002410) with 3.2334 million shares from equity incentive restrictions - Ningbo Port (601018) with 3.647 billion shares from A-share issuance to legal person allocation - Zhongjin Environment (300145) with 852,070 shares from equity incentive restrictions - Keli Ke (002782) with 768,000 shares from equity incentive restrictions - Yingjie Electric (300820) with 62,500 shares from equity incentive restrictions - Laobaixing (603883) with 868,400 shares from equity incentive restrictions - Zhaoxun Media (301102) with 218 million shares from extended lock-up period - Zhongjing Technology (003026) with 20,000 shares from equity incentive restrictions - Woge Optoelectronics (603773) with 14.8003 million shares from A-share issuance to original shareholders allocation - Hanrui Cobalt (300618) with 104,670 shares from equity incentive restrictions - Fujilai (301258) with 55.362 million shares from extended lock-up period - Wankai New Materials (301216) with 225 million shares from extended lock-up period - Weiteou (301319) with 29.8 million shares from pre-issue share restrictions - Guanshi Technology (605588) with 19,870 shares from equity incentive restrictions - Sanwang Communication (688618) with 13,500 shares - Xidi Micro (688173) with 771,800 shares - Rendu Biology (688193) with 8.4316 million shares - Jinchang Protein (688137) with 7.145 million shares - Jiao Cheng Ultrasound (688392) with 43.8612 million shares - Aike Saibo (688719) with 824,800 shares [1]

Group 1 - The core viewpoint of the news is that Rendu Biotech has shown fluctuations in its stock performance, with a year-to-date increase of 34.89% and a recent drop of 10.11% over the past 20 days [1] - As of June 30, the number of shareholders for Rendu Biotech increased by 7.54% to 3,495, while the average circulating shares per person decreased by 7.01% to 9,032 shares [2] - The company reported a revenue of 81.24 million yuan for the first half of 2025, representing a year-on-year decrease of 6.27%, and a net profit of 2.04 million yuan, down 52.94% year-on-year [2] Group 2 - Rendu Biotech has a market capitalization of 1.93 billion yuan and its stock price was 48.09 yuan per share as of September 25 [1] - The company's main business revenue composition includes 90.04% from reagent business, 8.49% from instrument business, and 1.47% from testing services [1] - Since its A-share listing, Rendu Biotech has distributed a total of 20.58 million yuan in dividends [3]

Core Viewpoint - The company is set to release 8,431,604 restricted shares for trading on September 30, 2025, following a 42-month lock-up period since its initial public offering (IPO) [4][5][21]. Group 1: Stock Listing Details - The type of stock listing is for the first issuance of restricted shares, with a total of 8,431,604 shares to be listed [2][3]. - The total number of shares after the IPO was 40,000,000, with 31,818,377 shares (79.55%) being restricted and 8,181,623 shares (20.45%) being unrestricted [5]. - The restricted shares being released are held by two shareholders and represent 21.04% of the total share capital [5]. Group 2: Shareholder Commitments - The controlling shareholder, Ju Jinliang, has committed to not transferring or managing the shares held prior to the IPO for 36 months and has additional conditions for extending the lock-up period if the stock price falls below the IPO price [7][8]. - There are specific commitments regarding the sale of shares after the lock-up period, including a requirement that any sales must not be below the IPO price and must be disclosed in advance [14][17]. - The company has confirmed that there are no instances of fund occupation by the controlling shareholder or related parties [21]. Group 3: Regulatory Compliance - The company has received approval from the China Securities Regulatory Commission for the public issuance of shares and has complied with the relevant regulations for the listing of restricted shares [5][21]. - The underwriter has verified that the company has adhered to the commitments regarding share lock-up and that the information disclosed is accurate and complete [21].

Group 1 - The core point of the article is that Rendu Biotech announced the listing of its shares, which will be subject to a lock-up period and will be available for trading starting September 30, 2025 [1] - The type of stock listing is a first-time restricted share offering, with a total of 8,431,604 shares being listed [1] - The method of stock subscription is offline, indicating a specific approach to how investors can acquire these shares [1]

中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 首次公开发行部分限售股上市流通的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上海仁 度生物科技股份有限公司（以下简称"仁度生物"或"公司"）首次公开发行股票并在 科创板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易 所科创板股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督 导》等有关法律法规和规范性文件的要求，对仁度生物首次公开发行部分限售股解禁上 市流通事宜进行了核查，发表核查意见如下： 一、本次上市流通的限售股类型 经中国证券监督管理委员会于 2022 年 2 月 15 日出具的《关于同意上海仁度生物科 技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕332 号）同意，公 司获准向社会公开发行人民币普通股（A 股）10,000,000 股，并于 2022 年 3 月 30 日在 上海证券交易所科创板挂牌上市。公司首次公开发行 A 股前总股本为 30,000,000 股， 首次公开发行 A 股后总股本为 40,000,000 股，其中有限售条件流通股为 ...

一、本次上市流通的限售股类型 经中国证券监督管理委员会于2022年2月15日出具的《关于同意上海仁度生物 科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕332号）同 意，公司获准向社会公开发行人民币普通股（A股）10,000,000股，并于2022年3 月30日在上海证券交易所科创板挂牌上市。公司首次公开发行A股前总股本为 30,000,000股，首次公开发行A股后总股本为40,000,000股，其中有限售条件流通股 为31,818,377股，占总股本比例为79.55%，无限售条件流通股为8,181,623股，占总 股本比例为20.45%。 本次上市流通的限售股为公司首次公开发行前股东持有的部分限售股，涉及 限售股股东数量为2名，限售期限为自公司股票上市之日起42个月，该部分限售股 股东对应的股份总数为8,431,604股，占公司股本总数的21.04%。现锁定期即将届 满，上述限售股将于2025年9月30日起上市流通。 证券代码：688193 证券简称：仁度生物 公告编号：2025-040 上海仁度生物科技股份有限公司 关于公司首次公开发行部分限售股上市流通的公告 本公司董事会及全体董事保 ...

中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 2025 年半年度持续督导跟踪报告 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上海仁度 生物科技股份有限公司（以下简称"仁度生物"或"公司"）首次公开发行股票并在科创 板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所 科创板股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》 等相关规定，负责仁度生物上市后的持续督导工作，并出具本持续督导半年度跟踪报 告，具体情况如下： | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针对具体 的持续督导工作制定相应的工作计划 | 保荐机构已建立并有效执行了持 | | | | 续督导制度，并制定了相应的工 | | | | 作计划。 | | 2 | 根据中国证监会相关规定，在持续督导工作开始前， | 保荐机构已与公司签订《保荐协 | | | 与上市公司或相关当事人签署持续督导协议，明确双 | 议》，该协议明确了双方在持续 | | | 方在持续督导期间的权利义务 ...